Ladostigil(Ladostigil) - 药物靶点：MAO-A x MAO-B_在研适应症：认知功能障碍_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Ladostigil hemitartrate、Ladostigil tartrate、Ladostigil tartrate (USAN)

+ [2]

靶点

MAO-A x MAO-B

作用机制

MAO-A抑制剂(单胺氧化酶A抑制剂)、MAO-B抑制剂(单胺氧化酶B抑制剂)

治疗领域

其他疾病

在研适应症

认知功能障碍

非在研适应症

阿尔茨海默症遗忘痴呆+ [2]

原研机构

Teva Pharmaceutical Industries Ltd.

在研机构

Teva Pharmaceutical Industries Ltd.

非在研机构

Avraham Pharmaceuticals Ltd.

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

结构

分子式C20H26N2O8

InChIKeyDZMNQRCPJKPTNC-KBYGAXRISA-N

CAS号209394-46-7

查看全部结构式(2)

关联

4

项与 Ladostigil 相关的临床试验

NCT01429623 / Completed临床2期

A 36-month, Multi-centre, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment (MCI)

The purpose of this study is to determine whether treatment with the investigational drug ladostigil will delay the onset of Alzheimer's disease(AD) in patients with Mild Cognitive Impairment (MCI). MCI is now recognized as a precursor to AD and clinical tools are available to assess cognitive performance at this earlier stage. Ladostigil is currently under investigation for the treatment of AD. In this study, the investigators will be examining ladostigil at a lower dose level. At this dose level, ladostigil has been shown to reduce signs of early memory loss in animals. Thus, in this study the investigators are attempting to determine if earlier invention with a lower dose of ladostigil will significantly reduce initial memory loss and delay the subsequent progression to more serious cognitive dysfunction.

开始日期2012-02-01

申办/合作机构

Avraham Pharmaceuticals Ltd.

EUCTR2010-019858-41-DE / Not yet recruitingN/A

A 6-month prospective, multi-center, double-blind, placebo-controlled, randomized, adaptive-trial-design study to evaluate the safety and efficacy of 80mg b.i.d. ladostigil in patients with mild to moderate probable Alzheimer’s Disease with a 6-month open label follow-up period - CR100101/CO15570

开始日期2011-02-09

申办/合作机构

Avraham Pharmaceuticals Ltd.

NCT01354691 / Completed临床2期

A 6-Month Prospective, Multi-Center, Double-Blind, Placebo-Controlled, Randomized, Adaptive-Trial-Design Study to Evaluate the Safety and Efficacy of 80mg b.i.d Ladostigil in Patients With Mild to Moderate Probable Alzheimer's Disease

For many, Alzheimer's disease is the number one medical issue facing our aging society. It is a late onset neurodegenerative disease, frequently under diagnosed, that impairs memory and cognitive performance. There are no known treatments that can either prevent or reverse its progression. Consequently, there still remains a need to evaluate treatments which can better stabilize the symptoms of this disease. These symptoms frequently include decreased functional capacity and negative psychological attributes (e,g, depression, anxiety) in association with the memory and cognition deficits. This current study is being done to assess an investigational compound that has been designed to not only improved the cognitive status of affected patients but to also better manage all symptoms. Hence, the ultimate goal is to provide patients with an improved quality of life by slowing the progression of this neurodegenerative disease

开始日期2011-02-01

申办/合作机构

Avraham Pharmaceuticals Ltd.

100 项与 Ladostigil 相关的临床结果

登录后查看更多信息

100 项与 Ladostigil 相关的转化医学

登录后查看更多信息

100 项与 Ladostigil 相关的专利（医药）

登录后查看更多信息

59

项与 Ladostigil 相关的文献（医药）

2021-02-01·Iranian journal of basic medical sciences4区 · 医学

Alzheimer's disease treatment: The share of herbal medicines.

4区 · 医学

ReviewOA

作者: Hamidi, Gholamali ; Salami, Mahmoud ; Karimian, Mohammad ; Soheili, Masoud

One of the most frequent forms of dementia in neurological disorders is Alzheimer's disease (AD). It is a chronic neurodegenerative disease characterized by impaired learning and memory. Pathological symptoms as extracellular amyloid-beta (Aβ) plaques and intracellular accumulation of neurofibrillary tangles occur in AD. Due to the aging of the population and increased prevalence of AD, discovery of new therapeutic agents with the highest effectiveness and fewer side effect seems to be necessary. Numerous synthetic medicines such as tacrine, donepezil, galantamine, rivastigmine, memantine, glutathione, ascorbic acid, ubiquinone, ibuprofen, and ladostigil are routinely used for reduction of the symptoms and prevention of disease progression. Nowadays, herbal medicines have attracted popular attention for numerous beneficial effects with little side effects. Lavandula angustifolia, Ginkgo biloba, Melissa officinalis, Crocus sativus, Ginseng, Salvia miltiorrhiza, and Magnolia officinalis have been widely used for relief of symptoms of some neurological disorders. This paper reviews the therapeutic effects of phytomedicines with prominent effects against various factors implicated in the emergence and progression of AD.

2020-10-26·Current Pharmaceutical Design4区 · 医学

Exploring the Multifunctional Neuroprotective Promise of Rasagiline Derivatives for Multi-Dysfunctional Alzheimer’s Disease

4区 · 医学

Article

作者: Kabir, Md Tanvir ; Alim, Md Abdul ; Khatkar, Anurag ; Ashraf, Ghulam Md ; Rauf, Abdur ; Al Mamun, Abdullah ; Uddin, Md Sahab ; Rahman, Md Habibur ; Rahman, Md Motiar ; Mathew, Bijo

Alzheimer's disease (AD) is a chronic, age-related, and irreversible brain disorder that typically develops slowly and gets worse over time. The potent auspicious drug candidate for the treatment of AD is supposed to perform the simultaneous modulation of several targets linked to AD. The new therapeutic approach involves drug candidates that are designed to act on multiple targets and have various pharmacological properties. This trend has triggered the development of various multimodal drugs including TV-3326 (i.e. ladostigil) and M-30 (i.e. a new multitarget iron chelator). TV-3326 combines the neurorestorative/neuroprotective effects of the cholinesterase (ChE) inhibitory activity of rivastigmine with rasagiline (a selective monoamine oxidase-B inhibitor and novel antiparkinsonian agent) in a single molecule. M-30, the second derivative of rasagiline, was developed by combining the propargyl moiety of rasagiline into the skeleton of VK-28 (i.e. a novel brain permeable neuroprotective iron chelator). It has been revealed that both the compounds possess anti-AD effects and therefore, the clinical development is directed to the treatment of this type of neurodegenerative diseases (NDs). In this article, we have reviewed the neuroprotective molecular mechanisms and multimodal effects of TV-3326 and M-30.

2020-10-01·Neuropharmacology2区 · 医学

Effect of ladostigil treatment of aging rats on gene expression in four brain areas associated with regulation of memory

2区 · 医学

Article

作者: Linial, Michal ; Weinstock, Marta ; Stern, Amos

Episodic and spatial memory decline in aging and are controlled by the hippocampus, perirhinal, frontal and parietal cortices and the connections between them. Ladostigil, a drug with antioxidant and anti-inflammatory activity, was shown to prevent the loss of episodic and spatial memory in aging rats. To better understand the molecular effects of aging and ladostigil on these brain regions we characterized the changes in gene expression using RNA-sequencing technology in rats aged 6 and 22 months. We found that the changes induced by aging and chronic ladostigil treatment were brain region specific. In the hippocampus, frontal and perirhinal cortex, ladostigil decreased the overexpression of genes regulating calcium homeostasis, ion channels and those adversely affecting synaptic function. In the parietal cortex, ladostigil increased the expression of several genes that provide neurotrophic support, while reducing that of pro-apoptotic genes and those encoding pro-inflammatory cytokines and their receptors. Ladostigil also decreased the expression of axonal growth inhibitors and those impairing mitochondrial function. Together, these actions could explain the protection by ladostigil against age-related memory decline.

100 项与 Ladostigil 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D03239	-	-	DB16213

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
遗忘	临床3期	奥地利	Avraham Pharmaceuticals Ltd.	2011-02-01
遗忘	临床3期	德国	Avraham Pharmaceuticals Ltd.	2011-02-01
遗忘	临床3期	克罗地亚	Avraham Pharmaceuticals Ltd.	2011-02-01
遗忘	临床3期	塞尔维亚	Avraham Pharmaceuticals Ltd.	2011-02-01
遗忘	临床3期	西班牙	Avraham Pharmaceuticals Ltd.	2011-02-01
记忆障碍	临床3期	塞尔维亚	Avraham Pharmaceuticals Ltd.	2011-02-01
记忆障碍	临床3期	克罗地亚	Avraham Pharmaceuticals Ltd.	2011-02-01
记忆障碍	临床3期	西班牙	Avraham Pharmaceuticals Ltd.	2011-02-01
记忆障碍	临床3期	奥地利	Avraham Pharmaceuticals Ltd.	2011-02-01
认知功能障碍	临床2期	-	Teva Pharmaceutical Industries Ltd.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01354691 (CTgov)	临床2期	阿尔茨海默症 \| 认知功能障碍 \| 遗忘	200	ladostigil hemitartrate (Ladostigil Hemitartrate)	餘鏇窪觸鹽膚膚醖鹹製(齋製繭夢鬱構構憲獵襯) = 鏇簾鬱壓築艱艱壓網衊製廠鹽窪壓襯膚淵獵衊 (窪鬱顧積鹹襯網遞醖襯, 餘醖鏇憲窪膚醖餘廠繭 ~ 選鹹衊製壓鏇鹽鏇淵願) 更多	-	2020-07-30
				ladostigil hemitartrate (Placebo)	餘鏇窪觸鹽膚膚醖鹹製(齋製繭夢鬱構構憲獵襯) = 顧築鑰膚獵顧鑰窪願憲製廠鹽窪壓襯膚淵獵衊 (窪鬱顧積鹹襯網遞醖襯, 膚繭選鏇糧範淵淵衊鹹 ~ 遞衊艱廠鑰鹽餘鏇廠觸) 更多
NCT01429623 (CTgov)	临床2期	轻度认知障碍 \| 痴呆	210	ladostigil hemitartrate (Ladostigil Hemitartrate)	膚願膚範顧網願獵壓淵(窪構艱製鑰憲齋鏇膚顧) = 蓋觸壓衊鬱觸築膚願鹽範觸鹽餘顧窪鏇鬱壓襯 (壓襯製繭鏇衊簾製遞壓, 簾艱壓願鑰餘鹽鏇範淵 ~ 構蓋願簾鏇餘憲壓鑰壓) 更多	-	2017-06-15
				Placebo (Placebo Control)	膚願膚範顧網願獵壓淵(窪構艱製鑰憲齋鏇膚顧) = 齋糧廠範觸範窪觸獵憲範觸鹽餘顧窪鏇鬱壓襯 (壓襯製繭鏇衊簾製遞壓, 鬱選鹹餘積蓋網選廠獵 ~ 顧遞醖鏇餘構顧選範積) 更多